BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon

byakkaya BridgeBio Pharma Inc. (NASDAQ:BBIO) is a biopharmaceutical company that focuses on developing innovative therapies for genetic diseases. The company’s research and development platform uses a threefold approach to managing costs and timelines effectively: streamlined discovery, decentralized teams, and efficient development processes. BBIO’s pipeline includes late-stage drug candidates like Acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM). The company also has other Phase 3 drug ca ...